InvestorsHub Logo
Followers 129
Posts 7014
Boards Moderated 0
Alias Born 04/14/2013

Re: None

Thursday, 06/15/2017 10:44:57 AM

Thursday, June 15, 2017 10:44:57 AM

Post# of 2340315
$TAUG +87%%%% WEEEEEEEEEEEEEEEEEEEEEEEE



Thursday, June 15 2017 8:00 AM, EST Tauriga Sciences Inc. Discloses Personal Investment of $95,000 USD from its Chief Executive Officer Seth M. Shaw; Investment Structured as Equity Private Placement Priced at $0.00125 Marketwire   "Press Releases"
NEW YORK, NY -- (Marketwired) -- 06/15/17 -- Tauriga Sciences Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"), a company engaged in the building of life sciences businesses and technologies, has today announced that is Chief Executive Officer ("CEO"), Mr. Seth M. Shaw ("Mr. Shaw"), has made a personal investment into the Company totaling $95,000 USD at this time. This personal investment was structured as an equity Private Placement at a price of $0.00125 ("one eighth of one cent "), for a total of 76,000,000 shares (a Form 4 reflecting this insider purchase will be filed within the next several business days). The Company will utilize this infusion of working capital for general and administrative purposes; these 76,000,000 shares will not be issued until the Company has successfully amended its Shares Authorized.

Tauriga's CEO, Seth M. Shaw , expressed, "At this time, I believe it is of great importance to demonstrate to shareholders my unwavering commitment to both restoring and creating long term shareholder value. This $95,000 USD will help the Company satisfy some short term commitments & invoices and enable Tauriga to approach the second half of Calendar Year 2017 with a greater degree of strength, flexibility, and confidence."

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company's previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it's seeking monetary damages in excess of $4,500,000 USD .



Disclaimer: Everything I post is my opinion only and is not to be construed as investment advice. You make your own buy/sell decisions based on your own judgement. I'll sometimes post bearish or bullish remarks. Do not take this as investment advice.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.